What's new? Log in Free sign up

Qiagen (QGEN) News and press releases

Company Profile

News

From Benzinga Pro

QIAGEN and Servier Unite to Develop Companion Diagnostic for Acute Myeloid Leukemia Therapy Drug

QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)))) today announced it has entered into a strategic partnership with Servier, a global pharmaceutical group, to develop a companion diagnostic test for TIBSOVO®,

'Qualigen Peer-Reviewed Journal Article Out Titled "The Potent G-Quadruplex-Binding Compound QN-302 Downregulates S100p Gene Expression In Cells And In An In Vivo Model Of Pancreatic Cancer"'

Biotech, News, FDA, General

https://www.mdpi.com/1420-3049/28/6/2452 Abstract The naphthalene diimide compound QN-302, designed to bind to G-quadruplex DNA sequences within the promoter regions of cancer-related genes, has high anti-proliferative

SOPHiA GENETICS And QIAGEN Forge Partnership To Combine Strengths In Next-generation Sequencing

SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company in the healthcare space, today announced a new partnership with QIAGEN N.V. (NYSE:QGEN) that will pair QIAseq reagent technology with the SOPHiA

UBS Maintains Neutral on Qiagen, Raises Price Target to $52

News, Price Target, Analyst Ratings

UBS analyst John Sourbeer maintains Qiagen (NYSE:QGEN) with a Neutral and raises the price target from $50 to $52.

Citigroup Maintains Buy on Qiagen, Raises Price Target to $60

News, Price Target, Analyst Ratings

Citigroup analyst Patrick Donnelly maintains Qiagen (NYSE:QGEN) with a Buy and raises the price target from $55 to $60.

Qiagen Q4 EPS $0.53 Beats $0.47 Estimate, Sales $498.00M Beat $486.47M Estimate

Qiagen (NYSE:QGEN) reported quarterly earnings of $0.53 per share which beat the analyst consensus estimate of $0.47 by 12.77 percent. This is a 28.38 percent decrease over earnings of $0.74 per share from the same

Earnings Scheduled For February 7, 2023

Companies Reporting Before The Bell • BP (NYSE:BP) is likely to report quarterly earnings at $1.67 per share on revenue of $53.79 billion.

Genetic Technologies Shares Jump After Strategic Alliance With Qiagen

Large Cap, News, Penny Stocks, Health Care, Movers, General

Genetic Technologies Limited (NASDAQ: GENE) agreed to form a strategic alliance with Qiagen NV (NYSE: QGEN) to establish and develop a 'Centre of Excellence facility in Australia.

Qualigen Therapeutics CEO Michael Poirier Provides Letter To Stockholders

Qualigen Therapeutics, Inc. (("Qualigen" or "the Company, NASDAQ:QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug

Reported Earlier, 'Qiagen Weighs Stake Sale In $1B Bioinformatics Arm' - Bloomberg News

News, Asset Sales

https://www.bloomberg.com/news/articles/2023-01-27/qiagen-said-to-weigh-stake-sale-in-1-billion-bioinformatics-arm?cmpid=socialflow-twitter-business&utm_content=business&utm_medium=social&utm_source=twitter&a

Reported Monday January 23, 'QIAGEN Digital Insights Launches Ultra-Fast NGS Analysis Able To Process A Whole Genome In 25 Minutes For A $1 In Cloud Computing Costs'

https://corporate.qiagen.com/English/newsroom/press-releases/press-release-details/2023/QIAGEN-Digital-Insights-launches-ultra-fast-NGS-analysis-able-to-process-a-whole-genome-in-25-minutes-for-a-1-in-cloud-computing-cos

Tesla's Delivery Wait Times Go Up, China Wants To Secure License For Generic Version Of Pfizer's Paxlovid, India-Made iPhone Exports Surpass $2.5B: Today's Top Stories

Biotech, Large Cap, M&A, News, Penny Stocks, Health Care, Small Cap, FDA, Top Stories, Markets, Movers, Tech, Media, Trading Ideas, General

QIAGEN Acquires Verogen Strengthening Its Position In Human ID / Forensics

Large Cap, M&A, News, Health Care, General

QIAGEN And Helix Launch Exclusive Partnership To Advance Next-Generation Sequencing Companion Diagnostics In Hereditary Diseases

Partnership to leverage the Helix® Laboratory Platform powered by QIAGEN’s biopharma relationships, NGS capabilities, and global regulatory expertise Addressing health burden in neuro-degenerative

Press releases

From Benzinga Pro

QIAGEN Announces Form 20-F Annual Report Filing for 2022 Results

QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2022,

QIAGEN and Servier Partner to Develop Companion Diagnostic for Acute Myeloid Leukemia (AML) Therapy Drug

QIAGEN to develop PCR test to detect isocitrate dehydrogenase-1 (IDH1) mutations in AML patients to be used with Servier's marketed and investigational targeted treatment Test for blood and bone marrow samples to

QIAGEN's tuberculosis blood test QuantiFERON-TB Gold Plus gains CE-marking under new EU IVDR framework

Certification of QuantiFERON-TB Gold Plus under more stringent EU regulation, classified under Class C Certification marks milestone in QIAGEN's transition to full compliance with new EU regulations for IVD

QIAGEN Exceeds Outlook for Fourth Quarter and Full-Year 2022 With 14% CER Sales Growth in FY 2022 From Non-COVID Product Groups

Q4 2022: Net sales of $498 million (-14% at actual rates, -9% at constant exchange rates, CER); diluted EPS of $0.39 and adjusted diluted EPS of $0.53 Net sales at CER of $531 million vs. outlook for at least $520

QIAGEN Launches EZ2 Connect MDx Platform for Automated Sample Processing in Diagnostic Labs

Start of worldwide diagnostic use follows the launch of upgraded EZ2 Connect for research use in 2021, builds on the success of EZ1 Connect platform found in thousands of labs worldwide EZ2 Connect MDx puts

QIAGEN N.V. to Release Results for Q4 and Full-Year Results 2022 and Hold Webcast

QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the fourth quarter and full-year 2022. Press release date / time: Tuesday, February 7, shortly after 22:05 Frankfurt

QIAGEN Completes Acquisition of Verogen, Strengthening Leadership in Human ID / Forensics With NGS Technologies

Verogen a proven leader in equipping forensic science laboratories and criminal investigators to use next-generation sequencing (NGS) to gain deeper insights Addition of Verogen strengthens QIAGEN leadership in

Helix and QIAGEN Form Exclusive Global Partnership to Develop and Commercialize Companion Diagnostics for Hereditary Diseases

Partnership to leverage the Helix® Laboratory Platform and QIAGEN's biopharma relationships, NGS capabilities, and global regulatory expertise Addressing health burden in neuro-degenerative diseases,

QIAGEN and Helix Launch Exclusive Partnership to Advance Next-Generation Sequencing Companion Diagnostics in Hereditary Diseases

Partnership to leverage the Helix® Laboratory Platform powered by QIAGEN's biopharma relationships, NGS capabilities, and global regulatory expertise Addressing health burden in neuro-degenerative diseases,

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.